newsfilter
← Latest News
Business Wire·

AVROBIO to Present New Clinical and Preclinical Data at the ASGCT 25th Annual Meeting

AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that new data from its ongoing, collaborator-sponsored1 Phase 1/2 clinical trial in cysti